drugset / Trial / NCT04398225

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder

NCT04398225

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial will evaluate the pharmacokinetics, safety, and tolerability of centanafadine in pediatric subjects with ADHD.

Timeline

Start
2020-06-11
Primary completion
2021-04-01
Completion
2021-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Centanafadine Small molecule 100 mg Oral
Subject Centanafadine Small molecule 200 mg Oral
Subject Centanafadine Small molecule 400 mg Oral